Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemotherapy

Share :
Published: 28 Sep 2014
Views: 2889
Rating:
Save
Dr Tony Mok - The Chinese University of Hong Kong, Shatin, China

At a press conference at ESMO 2014, Dr Mok presents the results of a phase 3 trial which found that patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy.

Read the news story for more.